[Federal Register Volume 79, Number 26 (Friday, February 7, 2014)]
[Notices]
[Pages 7477-7478]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-02597]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; 
Catalent CTS, Inc.

    Pursuant to 21 CFR 1301.34(a), this is notice that on September 23, 
2013, Catalent CTS, Inc., 10245 Hickman Mills Drive, Kansas City, 
Missouri 64137, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as an importer of the following 
basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Poppy Straw Concentrate (9670).............  II
------------------------------------------------------------------------

    The company plans to import a finished pharmaceutical product 
containing cannabis extracts in dosage form for a clinical trial study.
    In reference to drug code 7360, the company plans to import a 
synthetic cannabidiol. This compound is listed under drug code 7360. No 
other activity for this drug code is authorized for this registration.
    In addition, the company plans to import an ointment for the 
treatment of wounds which contain trace amounts of the controlled 
substances normally found in poppy straw concentrate for packaging and 
labeling to be used in clinical trials.
    Comments and requests for any hearings on applications to import 
narcotic raw material are not appropriate. 72 FR 3417 (January 25, 
2007).
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedules I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in 
the circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant

[[Page 7478]]

to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODW), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than March 10, 2014.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, 40 FR 43745-46, all applicants for 
registration to import a basic class of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-02597 Filed 2-6-14; 8:45 am]
BILLING CODE 4410-09-P